ProfileGDS5678 / 1443036_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 42% 42% 40% 41% 43% 45% 41% 42% 42% 42% 42% 42% 42% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0022842
GSM967853U87-EV human glioblastoma xenograft - Control 22.9677342
GSM967854U87-EV human glioblastoma xenograft - Control 32.9678842
GSM967855U87-EV human glioblastoma xenograft - Control 42.8649640
GSM967856U87-EV human glioblastoma xenograft - Control 52.8994741
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0879743
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1134145
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9456941
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9474842
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.962542
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.957342
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9385142
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9710542
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9632942